Although the findings of initial trials on ICIs for CRC were not promising, the mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) subset is currently regarded as an excellent target for anti-PD-1/anti-PD-L1 immunotherapy [3,4]. Here, PDCD1 is linked to colorectal carcinoma.